Assessment of severity of Parkinson Disease clinical trials

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

This study is looking into a new medication called pimavanserin for people with Parkinson's disease who also experience impulse control disorders (ICDs). The aim is to see if this medicine can help manage these behaviours safely and effectively.